人甲状腺癌小鼠移植性模型的抗癌治疗研究进展

doi:10.3969/j.issn.1006-6233.2021.09.039

摘要
图/表
参考文献
相关文章 (15)

[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2018,68(6):394~424.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer Clin,2016,66(2):115~132.
[3] 祝捷,曹东.复发性分化型甲状腺癌再次手术病理改变及预后影响因素[J].浙江创伤外科,2020,25(6):1070~1071.
[4] 郑永胜,苏国强.小鼠模型在甲状腺癌研究中的应用进展[J].医学综述,2012,18(13):2016~2019.
[5] Watabe T,Kaneda-Nakashima K,Liu Y,et al.Enhancement of 211at uptake via the sodium iodide symporter by the addition of ascorbic acid in targeted α-therapy of thyroid cancer[J].Journal of nuclear medicine:official publication,Society of Nuclear Medicine,2019,60(9):1301~1307.
[6] Saad F,Carles J,Gillessen S,et al.Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer:an international,early access,open-label,single-arm phase 3b trial[J].Lancet Oncol,2016,17(9):1306~1316.
[7] Haddad RI,Nasr C,Bischoff L,et al.NCCN guidelines insights:thyroid carcinoma,version 2.2018[J].Natl Compr Canc Netw,2018,16(12):1429~1440.
[8] Xiong L,Lin XM,Nie JH,et al.Resveratrol and its nanoparticle suppress doxorubicin/docetaxel-resistant anaplastic thyroid cancer cells in vitro and in vivo[J].Nanotheranostics,2021,5(2):143~154.
[9] Pan Y,Liu P,Chen D,et al.Small interfering RNA (siRNA) against slug induces apoptosis and sensitizes human anaplastic thyroid carcinoma cells to doxorubicin[J].Cancer Biomark,2017,18(4):357~366.
[10] Ngo B,Van Riper JM,Cantley LC,et al.Targeting cancer vulnerabilities with high-dose vitamin C[J].Nat Rev Cancer,2019,19(5):271~282.
[11] Su X,Shen Z,Yang Q,et al.Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms[J].Theranostics,2019,9(15):4461~4473.
[12] Ruan X,Shi X,Dong Q,et al.Antitumor effects of anlotinib in thyroid cancer[J].Endocr Relat Cancer,2019,26(1):153~164.
[13] Kim SY,Kim SM,Chang HJ,et al.SoLAT (Sorafenib Lenvatinib alternating treatment):a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer[ED/OL].BMC Cancer,2018,18(1).
[14] Pinto N,Prokopec SD,Ghasemi F,et al.Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models[ED/OL].PLoS One,2020,15(9).
[15] Junghans RP.The challenges of solid tumor for designer CAR-T therapies:a 25-year perspective[J].Cancer Gene Ther,2017,24(3):89~99.
[16] Vedvyas Y,McCloskey JE,Yang Y,et al.Manufacturing and preclinical validation of CAR T cells targeting ICAM-1 for advanced thyroid cancer therapy[ED/OL].Scientific reports,2019,9(1).